Site-Specific Antibody Conjugation Service
CD BioGlyco provides an integrated solution of Antibody Glycoengineering. Our advanced Glycoengineering Platform and high-quality site-specific antibody conjugation services will fully meet your needs. We have the confidence to be your essential research assistant in the field of glycobiology.
Antibody-Drug Conjugates
Antibody-drug conjugates are a promising class of tumor-targeted therapeutic drugs. The cell selectivity of monoclonal antibodies can selectively destroy malignant cells while sparing healthy tissue. The key to the construction of this conjugate is the covalent linker between the two components. The combination of macromolecular biology and small-molecule chemistry is the key to the success of antibody-drug conjugates.
Site-Specific Conjugation Technologies
To improve conventional conjugation methods to generate these heterogeneous products, various site-specific methods have been developed. These methods conjugate functional small molecules to specific sites in antibody molecules, including cysteine, glutamine, unnatural amino acids, short peptide tags, and glycans. The resulting antibody-drug conjugates showed high homogeneity and potent antitumor activity both in vitro and in vivo.
Chemically defined antibody conjugates can be synthesized in commercially relevant yields and generate antibody-drug conjugates with improved properties relative to heteroconjugates formed by non-specific chemical modification. Site-specific antibody-drug conjugates produced by enzymatic modification also show improved stability and pharmacokinetics.
Fig.1 Strategies to functionalise cysteine-engineered antibodies to generate homogeneous antibody-drug conjugates. (Walsh, et al., 2021)
Site-Specific Antibody Conjugation Service at CD BioGlyco
CD BioGlyco provides advanced technologies for the site-specific conjugation of IgG with Alexa Fluor 488, Alexa Fluor 555, Alexa Fluor 647, biotin, DFO, or azide. The technologies sre implemented using Fc glycan remodeling and a click chemistry approach.
In addition, we provide you with custom antibody conjugate services if our existing site-specific antibody conjugation services do not meet your specific needs. Our custom conjugate services are efficient and quality-assured.
Our site-specific antibody conjugation with azide service includes the following two parts:
- Site-Specific Antibody Conjugation with MMAE
- Site-Specific Antibody Conjugation with PNU Anthracycline
Our workflow is designed to guide your project from initial concept to a high-quality, fully characterized conjugate. Each stage is supported by our team of expert scientists, ensuring clear communication and meticulous execution.
- Protocol Design
After understanding your specific research goals, target molecule, and desired payload, we will evaluate the physicochemical properties of the antibody and payload and, based on this, recommend the optimal site-specific conjugation strategy to achieve your project objectives.
- Antibody Production and Engineering
Antibodies for conjugation are prepared according to the research plan. If genetic engineering is selected, our team will develop recombinant antibodies with the desired site-specific reactive handles. For other approaches, we ensure the antibodies are purified and maintained under optimal buffer conditions for subsequent conjugation steps.
- Linker-Payload Synthesis and Activation
To prepare payloads for conjugation, we synthesize linker-payload molecules or purchase and activate your selected payload. Our expert chemists ensure that the linker is stable and the payload is functionalized with appropriate reactive groups for efficient and clean reaction with the designated binding site on the antibody.
- Site-Specific Conjugation and Reaction Optimization
This is the core step in bioconjugation. The prepared antibody is conjugated to the activated linker-payload under carefully controlled reaction conditions optimized for high yield and specificity.
- Purification and Quality Control
The final conjugate is purified to remove any unconjugated payload, unreacted antibody, and other byproducts. We then perform a comprehensive series of quality control analyses, including mass spectrometry (MS) and size exclusion chromatography (SEC).
Workflow
Publication Data
Journal: Pharmaceuticals
IF: 4.8
Published: 2021
Results: This study uses native MS and ion mobility techniques to characterize a homogeneous site-specific antibody-drug conjugates, T-GlyCLICK-DM1, made via glycan remodeling and click chemistry. SEC-nMS tracked conjugation stages, confirming the end product's homogeneity. Thermal degradation studies via SEC-nMS identified aggregates and fragments but no drug deconjugation. Ion mobility-based collision-induced unfolding (CIU) showed drug conjugation boosted stability. These methods effectively monitor antibody-drug conjugates synthesis, degradation, and conformational changes for next-gen homogeneous antibody-drug conjugates characterization.
Fig.2 Schematic overview of the bioconjugation protocol. (Deslignière, et al., 2021)
Applications
- Site-specific conjugation is used to construct novel immunoconjugates for immunomodulation and cell therapy applications.
- By attaching fluorescent dyes, radioisotopes, or other imaging probes, our services enable the development of highly specific and reliable labeled antibodies for use in immunohistochemistry, flow cytometry, and in vivo molecular imaging.
- Researchers use our services to develop functionalized antibodies for various biochemical assays, protein-protein interaction studies, and immobilization on biosensor surfaces.
Advantages
- Unlike traditional random conjugation, our methods yield a single, well-defined product with a specific and consistent drug-to-antibody ratio (DAR).
- By precisely controlling the conjugation site, we ensure the payload does not interfere with the antibody's antigen-binding domain.
- Our core technologies allow us to adapt the conjugation strategy to your specific antibody and payload, whether you require a small-molecule drug, a fluorescent dye, or a chelator.
Frequently Asked Questions
With extensive experience, rich industry knowledge, and an advanced Glycoengineering Platform, CD BioGlyco is committed to making a difference in your program of site-specific antibody conjugation to develop a favorable candidate. Our world-class scientists and technicians will cooperate closely with our clients to accelerate the project. For more detailed information and quote, please feel free to contact us for deep communication.
Associated Services
To fully support your research and development journey, CD BioGlyco offers a suite of complementary services and products that can be seamlessly integrated with our site-specific antibody conjugation service.
Glycosylation Site-specific ADC Development
As a full-service provider, we handle the entire ADC development process, from target identification and antibody selection to conjugation, in vitro assays, and pre-clinical analysis.
Antibody Glycoengineering Servivices
Our specialized services in glycobiology assist with glycoengineering your antibody to create novel site-specific conjugation sites or to optimize its function and stability.
Advanced Glycoprotein Analysis Services
We offer a range of advanced analytical services to fully characterize your antibody and its conjugate, including sequencing, post-translational modification analysis, and functional assays.
References
- Walsh, S.J.; et al. Site-selective modification strategies in antibody-drug conjugates. Chemical Society Reviews. 2021, 50(2): 1305-1353. (Open Access)
- Deslignière, E.; et al. State-of-the-art native mass spectrometry and ion mobility methods to monitor homogeneous site-specific antibody-drug conjugates synthesis. Pharmaceuticals. 2021, 14(6): 498. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform
- Site-Specific Antibody Conjugation with Azide
- Site-Specific Antibody Conjugation with Alexa Fluor 488
- Site-Specific Antibody Conjugation with Alexa Fluor 555
- Site-Specific Antibody Conjugation with Alexa Fluor 647
- Site-Specific Antibody Conjugation with Biotin
- Site-Specific Antibody Conjugation with DFO








